Lighthouse: melflufen, daratumumab, and dexamethasone versus daratumumab in relapsed/refractory multiple myeloma refractory to an imid and a proteasome inhibitor or with 3 prior lines of therapy
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
关键词
relapsed/refractory multiple myeloma relapsed/refractory,multiple myeloma,proteasome inhibitor,daratumumab,dexamethasone
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要